Bellicum Pharmaceuticals Inc | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (29)

View All

Latest Posts

About This Stock More About This Stock
Bellicum Is Worth A Look With Multiple Catalysts On The Way In 2nd Half Of 2019
Article By: Terry Chrisomalis
Thursday, September 5, 2019 8:46 AM EDT
Bellicum is a highly undervalued biotech. Especially, when you consider that it has two types of technology that can be utilized to potentially alter how CAR-T therapies are produced.
In this article: BLCM
Read
BIO 2017 International #1: CAR-T Therapies On Solid Tumors
Article By: Rod Raynovich
Thursday, June 22, 2017 11:45 PM EDT
CAR-T shows great promise against blood cancers but challenges remain for solid tumors. Bellicum Pharmaceuticals, Bluebird bio, Cellectis SA, Juno Therapeutics, Kite Pharma and Poseida Therapeutics are some of the major companies engaged in CAR-T.
In this article: JUNO, KITE, BLUE, CLLS, BLCM
Read
All Posts

Latest Tweets for $BLCM

No tweets yet!

PARTNER HEADLINES

$BLCM

Comments Status Updates
Bellicum Is Worth A Look With Multiple Catalysts On The Way In 2nd Half Of 2019
David A Romero • 9/11/2019 12:14:41 PM

How likely is finidng a partner for $BLCM?

Bellicum Is Worth A Look With Multiple Catalysts On The Way In 2nd Half Of 2019
Dick Kaplan • 9/8/2019 1:05:08 AM

Based on history, any catalyst will lead to new lows. $BLCM

1 to 2 of 2 comments